T-cell engagers reach clinical trials with genOway’s hCD3 mice

Biopharma partners have used our hCD3 mouse models to reach clinical trials

Using genOway’s humanized CD3 mouse models, AstraZeneca and Harpoon Therapeutics demonstrated the high efficacy of their TCEs, helping them advance to clinical trials.

‍

Tumor growth inhibition in genO-hCD3ε mice treated with HPN328, a TCE targeting DLL3

Adapted from Molloy et al., Mol Cancer Ther, 2024

‍

Tumor growth inhibition in genO-panhCD3 mice treated with AZD5863, a TCE targeting Claudin 18.2

Adapted from Gaspar et al., J Immunother Cancer, 2025

‍

What sets our hCD3 models apart?

Our models presents unique features:

• Extensively validated with biopharma partners for efficacy and safety assessment of TCEs, leading to INDs
• Conserved interaction with CD3γ, CD3δ and CD3ζ subunits​
• Physiological expression of hCD3​
• Functional T/B-cell cooperation

‍

The impact of our models on our partners' research

Here is a non exhaustive list of scientific articles that were published using our hCD3 models:

• An affinity-modulated T cell engager targeting Claudin 18.2 shows potent anti-tumor activity with limited cytokine release, Gaspar et al., J Immunother Cancer, 2025｜model used: genO-panhCD3

• A Novel B7-H4xCD3 Bispecific T Cell Engager (PF-07260437) Synergizes with Breast Cancer Standard of Care and Immune-Checkpoint Therapies, Abayasiriwardana et al., Mol Cancer Ther, 2025｜model used: genO-hCD3ε

• HPN328, a Trispecific T Cell-activating Protein Construct Targeting DLL3-Expressing Solid Tumors, Molloy et al., Mol Cancer Ther, 2024｜model used: genO-hCD3ε

• ‍Humanization of a strategic CD3 epitope enables evaluation of clinical T-cell engagers in a fully immunocompetent in vivo model, Zorn et al., Sci Rep, 2022｜model used: genO-hCD3ε